• How Mixing Controls mRNA LNP Performance

  2026-09-14

  A 2026 Nature Communications study shows that primary mixing technique can substantially alter the physicochemical properties and biological performance of mRNA lipid nanoparticles, even when other formulation variables are held constant. Its comparison of ten mixing approaches explains why manually prepared or laminar-mixed particles may not predict materials produced with turbulent-flow equipment at manufacturing scale.

• Starvation, ER Calcium, and Cell Fate in Bombyx mori

  2026-09-13

  A 2026 study in Bombyx mori identifies an ER-Ca2+-calpain signaling axis that helps determine whether starvation-stressed fat-body cells remain in an autophagic state or progress to apoptosis. The work connects energy depletion, SERCA and IP3R dysregulation, calcium overload, ATG5 cleavage, and caspase-3 activation, while showing that 2-APB can suppress several starvation-associated responses.

• BCAA Rheostat Restores HSC Replicative Fitness

  2026-09-12

  Bartram and colleagues identify a metabolic explanation for the progressive loss of hematopoietic stem cell fitness associated with accrued divisions: branched-chain amino acid use shifts from catabolic maintenance toward anabolic activity, accelerating the cell cycle and destabilizing lineage output. Their metabolite-replacement experiments suggest that division-dependent functional drift is at least partly reversible, providing a mechanistic framework for improving HSC preservation and regeneration.

• S Tag Peptide: Practical Fusion Workflow

  2026-09-11

  S Tag Peptide is a small, soluble RNase A-derived peptide used primarily as a genetically encoded fusion tag for recombinant protein detection, solubility assessment, and antibody-based purification workflows. It should not be treated as a standalone ribonuclease reagent, and ethanol-based formulation is unsuitable according to the product dossier.

• Ceftolozane/Tazobactam: Evidence and Research Implications

  2026-09-11

  This review examines how ceftolozane/tazobactam combines potent antipseudomonal cephalosporin activity with β-lactamase inhibition to address resistant Gram-negative infections. Its integrated discussion of mechanism, susceptibility, pharmacokinetics, pharmacodynamics, clinical trials, and safety provides a useful framework for interpreting experimental and translational antibacterial research.

• PKH26 Red Fluorescent Cell Linker Kit Guide

  2026-09-10

  The PKH26 Red Fluorescent Cell Linker Kit provides stable red labeling of cell membrane lipid regions for longitudinal cell tracing and proliferation-oriented assays. It is intended for membrane labeling in vitro or in vivo, not for intracellular targets, organelles, or other non-membrane structures.

• AMG 9810 TRPV1 Antagonist Workflows

  2026-09-10

  AMG 9810 provides a selective pharmacological handle for separating TRPV1-driven calcium entry and CGRP secretion from downstream sensory-cell effects. This guide combines practical calcium-imaging and CGRP workflows with a carefully bounded metabolic-stress extension inspired by AMPK–SQSTM1 research.

• Syringin and Sunitinib in Renal Cell Carcinoma

  2026-09-09

  The reference study identifies Syringin as a potential adjunct to sunitinib in renal cell carcinoma (RCC), linking reduced tumor-cell viability, migration, and survival to EGFR/PI3K/Akt pathway modulation. Its integrated use of network pharmacology, molecular docking, bioinformatics, cell assays, and Western blotting provides a mechanistic framework for studying sunitinib sensitivity, although the findings remain preclinical and require validation in additional models.

• A 83-01 (ALK inhibitor) for Reliable Cell Assays

  2026-09-09

  Learn how A 83-01 (ALK inhibitor), SKU A3133, can improve experimental interpretation in viability, proliferation, EMT, and organoid workflows by providing defined TGF-β/Smad pathway inhibition. This scenario-based guide covers mechanism, dosing, stock preparation, assay controls, data interpretation, and practical product-selection criteria.

• Meropenem Workflows for Carbapenem Resistance

  2026-09-08

  Build reproducible susceptibility, resistance, and transmission assays with Meropenem, a β-lactam antibiotic carbapenem designed for broad bacterial challenge studies. This workflow connects PBP inhibition to plasmid surveillance, helping researchers distinguish drug response from mobile carbapenemase-driven resistance.

• Taihangia rupestris Leaves: UPLC-MS/MS and Bioactivity

  2026-09-08

  This 2026 RSC Advances study combines UPLC-MS/MS chemical profiling with orthogonal antioxidant, α-glucosidase inhibition, affinity-screening, and molecular-docking approaches to compare wild and cultivated Taihangia rupestris leaves. Its central finding is that foothill cultivation can produce chemically richer, more active material than wild plants, supporting conservation-oriented sourcing while identifying candidate compounds for further antidiabetic research.

• Deracoxib Workflows for COX-2 Research

  2026-09-07

  Deracoxib supports exposure-aware inflammation assays, canine osteosarcoma viability studies, and combination-treatment screens. This guide translates reference findings into practical dosing, controls, troubleshooting steps, and decision points for separating COX-2 biology from nonspecific cytotoxicity.

• AMG 9810: TRPV1 Antagonism Under Stress

  2026-09-07

  AMG 9810 is a selective TRPV1 antagonist for dissecting calcium entry and neuropeptide signaling. This article develops a stress-aware assay framework that connects sensory neuron experiments with insights from AMPK–SQSTM1 metabolic-stress biology without conflating the two systems.

• Psoralen-Induced Cholestasis via ERK1/2

  2026-09-05

  Chen and colleagues showed that psoralen and isopsoralen, estrogen-like constituents of Psoraleae Fructus, induce cholestatic injury in zebrafish larvae while activating ERK1/2 and disrupting bile acid homeostasis. The study connects phytoestrogenic activity with ERK signaling and provides pharmacologic rescue evidence supporting ERK1/2 as a mechanistic target for further cholestasis research.

• Tamsulosin: α1A Mechanism and Research Uses

  2026-09-04

  Tamsulosin is a selective α1A-adrenergic receptor antagonist used to study smooth muscle relaxation, ureteral stone passage, and postoperative urinary retention. Product-dossier evidence reports improved stone expulsion, higher maximum urinary flow, and approximately 50% lower postoperative retention risk under specified clinical contexts.

7619 records 1/508 page Next 12345 下5页 Last page